keyword
MENU ▼
Read by QxMD icon Read
search

Phase III

keyword
https://www.readbyqxmd.com/read/29785577/atezolizumab-a-review-in-previously-treated-advanced-non-small-cell-lung-cancer
#1
REVIEW
Hannah A Blair
Atezolizumab (TECENTRIQ™), an immune checkpoint inhibitor, is an immunoglobulin G1 monoclonal antibody that binds to programmed death ligand 1 (PD-L1) and blocks its interactions with programmed death 1 and B7.1 receptors. Atezolizumab is approved as monotherapy in several countries worldwide for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have previously received chemotherapy. Approval was based on its clinical benefit in this setting in the phase II POPLAR and phase III OAK trials...
May 21, 2018: Targeted Oncology
https://www.readbyqxmd.com/read/29785143/pilot-study-of-the-antifibrotic-effects-of-the-multikinase-inhibitor-pacritinib-in-a-mouse-model-of-liver-fibrosis
#2
Suliman Al-Fayoumi, Taishi Hashiguchi, Yuka Shirakata, John Mascarenhas, Jack W Singer
Background: Fibrotic diseases result from an exuberant response to chronic inflammation. Myelofibrosis is the end result of inflammation in bone, caused by an inflammatory process triggered by production of abnormal myeloid cells driven by mutations affecting the JAK-STAT pathway. Inflammatory cytokine overproduction leads to increased mesenchymal cell proliferation, culminating in fibrosis. Although JAK2 inhibitors, such as the JAK1/2 inhibitor ruxolitinib and the JAK2/FLT3/CSF1R/IRAK1 inhibitor pacritinib suppress abnormal clone expansion in myelofibrosis, ruxolitinib does not appear to prevent or reverse bone-marrow fibrosis in most patients...
2018: Journal of Experimental Pharmacology
https://www.readbyqxmd.com/read/29785090/semen-brassicae-ameliorates-hepatic-fibrosis-by-regulating-transforming-growth-factor-%C3%AE-1-smad-nuclear-factor-%C3%AE%C2%BAb-and-akt-signaling-pathways-in-rats
#3
Si Cao, Baoping Zheng, Tao Chen, Xinfeng Chang, Bao Yin, Zhihua Huang, Ping Shuai, Limin Han
Purpose: There is no effective treatment for liver fibrosis, which is a common phase during the progression of many chronic liver diseases to cirrhosis. Previous studies found that Semen Brassicae therapy can effectively improve the clinical symptoms of patients with asthma, allergic rhinitis, and chronic lung diseases; however, its effects on liver fibrosis in rats and its possible mechanisms of action remain unclear. Methods: Rats were injected intraperitoneally with 4% thioacetamide aqueous solution (5 mL·kg-1 ) at a dose of 200 mg·kg-1 twice a week for 8 consecutive weeks to establish the liver fibrosis model and were then treated with different concentrations of Semen Brassicae extract...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29784470/immunogenicity-and-safety-of-menacwy-tt-a-meningococcal-conjugate-vaccine-co-administered-with-routine-childhood-vaccine-in-healthy-infants-a-phase-iii-randomized-study
#4
Ghassan Dbaibo, Juan Carlos Tinoco Favila, Magali Traskine, Archana Jastorff, Marie Van der Wielen
BACKGROUND: Invasive meningococcal disease has a high burden in young children, particularly during infancy. We investigated the immunogenicity and safety of a quadrivalent meningococcal conjugated vaccine (MenACWY-TT) co-administered with routine vaccines in healthy infants. METHODS: In this phase IIIb study (NCT01340898) conducted in 2 centers in Lebanon and Mexico, 750 infants were randomized (2:1:1) to receive MenACWY-TT according to 3 schedules: 3+1 (at ages 2, 4, 6 and 15-18 months; group ACWY3+1); 1+1 (at 6 and 15-18 months; group ACWY1+1) or single-dose at 15-18 months (group ACWY1)...
May 18, 2018: Vaccine
https://www.readbyqxmd.com/read/29784315/solid-phase-microextraction-of-phthalic-acid-esters-from-vegetable-oils-using-iron-iii-based-metal-organic-framework-graphene-oxide-coating
#5
Shuaihua Zhang, Qian Yang, Zhi Li, Wenjin Wang, Xiaohuan Zang, Chun Wang, Zhi Wang
A hybrid composite featuring an iron-based metal-organic framework Material of Institute Lavoisier-88(Fe) and graphene oxide (MIL-88(Fe)/GO) was synthesized and used as the solid-phase microextraction (SPME) coating. The SPME fiber was prepared by covalent bonding of the MIL-88(Fe)/GO composite onto the stainless steel substrate. The fiber had a good durability and allowed >100 replicate extractions. The developed method, which combined the MIL-88(Fe)/GO coated fiber based SPME with gas chromatography-flame ionization detection (GC-FID), achieved low limits of detection (0...
October 15, 2018: Food Chemistry
https://www.readbyqxmd.com/read/29784193/adjuvant-vascular-endothelial-growth-factor-targeted-therapy-in-renal-cell-carcinoma-a-systematic-review-and-pooled-analysis
#6
REVIEW
Maxine Sun, Lorenzo Marconi, Tim Eisen, Bernard Escudier, Rachel H Giles, Naomi B Haas, Lauren C Harshman, David I Quinn, James Larkin, Sumanta K Pal, Thomas Powles, Christopher W Ryan, Cora N Sternberg, Robert Uzzo, Toni K Choueiri, Axel Bex
CONTEXT: Contradictory data exist with regard to adjuvant vascular endothelial growth factor receptor (VEGFR)-targeted therapy in surgically managed patients for localized renal cell carcinoma (RCC). OBJECTIVE: To systematically evaluate the current evidence regarding the therapeutic benefit (disease-free survival [DFS] and overall survival [OS]) and grade 3-4 adverse events (AEs) for adjuvant VEGFR-targeted therapy for resected localized RCC. EVIDENCE ACQUISITION: A critical review of PubMed/Medline, Embase, and the Cochrane Library in January 2018 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement was performed...
May 18, 2018: European Urology
https://www.readbyqxmd.com/read/29784155/parental-knowledge-of-pediatric-eye-health-in-an-ophthalmology-clinic-setting-validation-and-delivery-of-the-eyee-questionnaire
#7
Natalia Fong, Bethany Easterbrook, Forough Farrokhyar, Kourosh Sabri
OBJECTIVE: We aimed to develop and assess the reliability of a questionnaire assessing parental knowledge on core topics in pediatric eye health. METHODS: In Phase I, the Evaluate Your Eye Education Questionnaire (EYEE-Q) was developed and distributed to ascertain face validity (n = 20). In Phase II, participants completed EYEE-Q twice to determine test-retest reliability (n = 40). In Phase III, EYEE-Q was administered to parents in a tertiary level pediatric ophthalmology clinic to assess knowledge (n = 193)...
June 2018: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
https://www.readbyqxmd.com/read/29784042/neoadjuvant-oxaliplatin-and-capecitabine-combined-with-bevacizumab-plus-radiotherapy-for-locally-advanced-rectal-cancer-results-of-a-single-institute-phase-ii-study
#8
Xin Yu, Qiao-Xuan Wang, Wei-Wei Xiao, Hui Chang, Zhi-Fan Zeng, Zhen-Hai Lu, Xiao-Jun Wu, Gong Chen, Zhi-Zhong Pan, De-Sen Wan, Pei-Rong Ding, Yuan-Hong Gao
BACKGROUND: Neoadjuvant chemoradiotherapy followed by surgery is recommended as the standard of care for locally advanced rectal cancer, reducing local recurrence but not distant metastasis. Intensified systemic therapy is warranted to reduce the risk of distant metastasis. The present study aimed to evaluate the safety and efficacy of neoadjuvant oxaliplatin and capecitabine (XELOX) combined with bevacizumab plus radiotherapy for locally advanced rectal cancer. METHODS: Patients with stages II to III rectal cancer received one cycle of induction chemotherapy and concurrent chemoradiotherapy with XELOX plus bevacizumab...
May 21, 2018: Cancer communications
https://www.readbyqxmd.com/read/29783587/re-randomized-phase-iii-trial-of-adjuvant-pazopanib-versus-placebo-after-nephrectomy-in-patients-with-localized-or-locally-advanced-renal-cell-carcinoma
#9
https://www.readbyqxmd.com/read/29782648/patient-preferences-for-topical-treatment-of-actinic-keratoses-a-discrete-choice-experiment
#10
D Kopasker, A Kwiatkowski, R N Matin, C A Harwood, F Ismail, J T Lear, J Thomson, Z Hasan, G N Wali, A Milligan, L Crawford, I Ahmed, H Duffy, C M Proby, P F Allanson
BACKGROUND: Treatment of actinic keratoses (AK) is a potentially effective strategy for prevention of cutaneous squamous cell carcinoma (cSCC). However, the patient perspective on potential benefits of AK treatment in terms of skin cancer reduction has received little attention to date. OBJECTIVES: (1) To investigate patient preferences for AK topical treatments using a discrete choice experiment (DCE); (2) To evaluate patient willingness to trade between clinical benefit and medical burden...
May 21, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29782487/systematic-interrogation-of-diverse-omic-data-reveals-interpretable-robust-and-generalizable-transcriptomic-features-of-clinically-successful-therapeutic-targets
#11
Andrew D Rouillard, Mark R Hurle, Pankaj Agarwal
Target selection is the first and pivotal step in drug discovery. An incorrect choice may not manifest itself for many years after hundreds of millions of research dollars have been spent. We collected a set of 332 targets that succeeded or failed in phase III clinical trials, and explored whether Omic features describing the target genes could predict clinical success. We obtained features from the recently published comprehensive resource: Harmonizome. Nineteen features appeared to be significantly correlated with phase III clinical trial outcomes, but only 4 passed validation schemes that used bootstrapping or modified permutation tests to assess feature robustness and generalizability while accounting for target class selection bias...
May 21, 2018: PLoS Computational Biology
https://www.readbyqxmd.com/read/29782276/-the-efficacy-of-rivaroxaban-in-reducing-the-risk-of-cardiovascular-events-in-patients-with-stable-ischemic-heart-disease-and-peripheral-disease-results-of-the-compass-trial
#12
N M Savina
The article considers modern approaches to the secondary prevention of cardiovascular events in patients with stable ischemic heart disease (IHD) and / or atherosclerosis of peripheral arteries (peripheral artery disease - PAD) with the oral anticoagulant rivaroxaban. The results of the first international prospective phase III study COMPASS for the evaluation of efficacy and safety of rivaroxaban including 27 395 patients with stable IHD or PAD, are discussed. The results of the study were presented at European Congress of Cardiology 2017...
March 2018: Kardiologiia
https://www.readbyqxmd.com/read/29782182/a-specifically-designed-multispecies-probiotic-supplement-relieves-seasonal-allergic-rhinitis-symptoms
#13
Annabelle M Watts, Amanda J Cox, Peter K Smith, Isolde Besseling-van der Vaart, Allan W Cripps, Nicholas P West
BACKGROUND: Probiotics are purported to reduce symptoms of allergic rhinitis. This study sought to determine the proportion of participants with an improvement in the mini Rhinoconjunctivitis Quality of Life Questionnaire (mRQLQ) in response to a multispecies probiotic supplement with a Simon Two-Stage design. METHODS: This study was based on a Simon Two-Stage Design for p1 -p0  = 0.18 to account for seasonal variation in symptoms. Under this design, ≥10 patients are required to exhibit an improvement in quality-of-life scores to determine that there was sufficient activity for the supplement to be considered effective...
May 21, 2018: Journal of Alternative and Complementary Medicine: Research on Paradigm, Practice, and Policy
https://www.readbyqxmd.com/read/29782163/stoichio-kinetic-modeling-of-fenton-chemistry-in-a-meat-mimetic-aqueous-phase-medium
#14
Khaled Oueslati, Aurelie Promeyrat, Philippe Gatellier, Jean-Dominique Daudin, Alain Kondjoyan
Fenton reaction kinetics, which involved an Fe(II)/Fe(III) oxidative redox cycle, were studied in a liquid medium that mimics meat physicochemical conditions. Muscle antioxidants (enzymes, peptides and vitamins) were added one by one in the medium to determine their respective effects on formation of superoxide and hydroxyl radicals. A stoichio-kinetic mathematical model was used to predict the formation of these radicals. The difference between experimental and predicted results was mainly due to iron reactivity, which had to be taken into account in the model, and to uncertainties on some of the rate constant values introduced in the model...
May 21, 2018: Journal of Agricultural and Food Chemistry
https://www.readbyqxmd.com/read/29779201/clinical-acceptability-of-trimetazidine-modified-release-80-mg-once-daily-versus-trimetazidine-modified-release-35-mg-twice-daily-in-stable-angina-pectoris
#15
Yuri M Pozdnyakov
INTRODUCTION: Trimetazidine (TMZ) is an anti-ischemic metabolic agent that has been shown to be efficacious in angina treatment, both in monotherapy and in combination. A new formulation of TMZ modified-release (MR) 80 mg was developed, which is to be taken once daily (od), instead of twice daily (bid) for the currently available TMZ MR 35 mg, with the aim of simplifying the medication regimen. METHODS: The present study was an international, multicenter, randomized, double-blind, parallel-group phase III study with a 12-week treatment period...
May 19, 2018: Cardiology and Therapy
https://www.readbyqxmd.com/read/29778368/oral-dydrogesterone-for-luteal-phase-support-in-fresh-in-vitro-fertilization-cycles-a-new-standard
#16
REVIEW
Georg Griesinger, Christophe Blockeel, Herman Tournaye
Oral dydrogesterone has been used for luteal phase support on an empirical basis since the early days of in vitro fertilization (IVF) treatment. Systematic comparisons of oral dydrogesterone with vaginal progesterone, so far considered to be the standard of care, started to appear in the middle 2000s. Recently, a large, randomized, double-blind, double-dummy phase III trial on the use of daily 30 mg oral dydrogesterone versus daily 600 mg micronized vaginal progesterone for LPS in IVF was published. This company-sponsored trial confirmed the efficacy findings from previous independent researchers and firmly established the noninferiority of daily 30 mg oral dydrogesterone for luteal phase support...
May 2018: Fertility and Sterility
https://www.readbyqxmd.com/read/29778172/nanoencapsulation-of-hexavalent-chromium-with-nanoscale-zero-valent-iron-high-resolution-chemical-mapping-of-the-passivation-layer
#17
Xiao-Yue Huang, Lan Ling, Wei-Xian Zhang
Solid phase reactions of Cr(VI) with Fe(0) were investigated with spherical-aberration-corrected scanning transmission electron microscopy (Cs-STEM) integrated with X-ray energy-dispersive spectroscopy (XEDS). Near-atomic resolution elemental mappings of Cr(VI)-Fe(0) reactions were acquired. Experimental results show that rate and extent of Cr(VI) encapsulation are strongly dependent on the initial concentration of Cr(VI) in solution. Low Cr loading in nZVI (<1.0wt%) promotes the electrochemical oxidation and continuous corrosion of nZVI while high Cr loading (>1...
May 2018: Journal of Environmental Sciences (China)
https://www.readbyqxmd.com/read/29777823/updated-efficacy-analysis-including-secondary-population-results-for-oak-a-randomized-phase-iii-study-of-atezolizumab-vs-docetaxel-in-patients-with-previously-treated-advanced-non-small-cell-lung-cancer
#18
L Fehrenbacher, J von Pawel, K Park, A Rittmeyer, D R Gandara, S Ponce Aix, J-Y Han, S M Gadgeel, T Hida, D L Cortinovis, M Cobo, D M Kowalski, F De Marinis, M Gandhi, B Danner, C Matheny, M Kowanetz, P He, F Felizzi, H Patel, A Sandler, M Ballinger, F Barlesi
INTRODUCTION: The efficacy and safety of atezolizumab vs docetaxel as second- or third-line treatment in patients with advanced non-small cell lung cancer in the primary (n=850; ITT850) and secondary (n=1225; ITT1225) efficacy populations of the randomized phase III OAK study at an updated data cutoff were assessed. METHODS: Patients received atezolizumab 1200mg or docetaxel 75mg/m2 intravenously every 3 weeks until loss of clinical benefit or disease progression, respectively...
May 16, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29777529/pharmacokinetics-of-ads-5102-amantadine-extended-release-capsules-administered-once-daily-at-bedtime-for-the-treatment-of-dyskinesia
#19
Robert A Hauser, Rajesh Pahwa, William A Wargin, Cindy J Souza-Prien, Natalie McClure, Reed Johnson, Jack T Nguyen, Rajiv Patni, Gregory T Went
BACKGROUND: Preclinical and clinical studies suggest amantadine immediate-release (IR) may reduce dyskinesia in Parkinson's disease (PD), although higher doses are associated with increased CNS adverse events (AEs). ADS-5102 is an extended release amantadine capsule formulation, designed for once-daily dosing at bedtime (qhs) to provide high concentrations upon waking and throughout the day, with lower concentrations in the evening. The pharmacokinetics (PK) of ADS-5102 were assessed in two phase I studies in healthy subjects, and a blinded, randomized phase II/III dose-finding study in PD patients...
May 18, 2018: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/29777404/randomized-trial-comparing-resection-of-primary-tumor-with-no-surgery-in-stage-iv-breast-cancer-at-presentation-protocol-mf07-01
#20
Atilla Soran, Vahit Ozmen, Serdar Ozbas, Hasan Karanlik, Mahmut Muslumanoglu, Abdullah Igci, Zafer Canturk, Zafer Utkan, Cihangir Ozaslan, Turkkan Evrensel, Cihan Uras, Erol Aksaz, Aykut Soyder, Umit Ugurlu, Cavit Col, Neslihan Cabioglu, Betül Bozkurt, Ali Uzunkoy, Neset Koksal, Bahadir M Gulluoglu, Bulent Unal, Can Atalay, Emin Yıldırım, Ergun Erdem, Semra Salimoglu, Atakan Sezer, Ayhan Koyuncu, Gunay Gurleyik, Haluk Alagol, Nalan Ulufi, Uğur Berberoglu, Mustafa Dulger, Omer Cengiz, Efe Sezgin, Ronald Johnson
BACKGROUND: The MF07-01 trial is a multicenter, phase III, randomized, controlled study comparing locoregional treatment (LRT) followed by systemic therapy (ST) with ST alone for treatment-naïve stage IV breast cancer (BC) patients. METHODS: At initial diagnosis, patients were randomized 1:1 to either the LRT or ST group. All the patients were given ST either immediately after randomization or after surgical resection of the intact primary tumor. RESULTS: The trial enrolled 274 patients: 138 in the LRT group and 136 in the ST group...
May 17, 2018: Annals of Surgical Oncology
keyword
keyword
9607
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"